John Smither
Board Member
GENELUX Corp (GNLX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About John Smither
John Smither is recorded as CFO at MBX Biosciences, Inc. (MBX) and Board Member at GENELUX Corp (GNLX). John Smither was last confirmed as CFO at Arcutis Biotherapeutics, Inc. (ARQT) in a filing dated April 29, 2025. Earlier roles on record: CFO at Arcutis Biotherapeutics, Inc. (ARQT) until March 31, 2021. MBX Biosciences, Inc. reported in an 8-K filed July 13, 2026 that John Smither was appointed Chief Financial Officer and principal financial officer, effective July 13, 2026. MBX Biosciences, Inc. reported in an 8-K filed February 27, 2026 that John Smither was appointed Chief Financial Officer, on an interim and part-time basis, effective March 2, 2026. MBX Biosciences, Inc. reported in an 8-K filed February 27, 2026 that John Smither was appointed Interim Chief Financial Officer, effective March 16, 2026. Equibles holds 5 filed executive changes naming John Smither; each is listed under recent activity with its source filing. The proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $2,102,418 for John Smither in fiscal 2024, including a base salary of $183,333. Disclosed compensation is on record for 3 fiscal years. John Smither has spoken on 2 earnings calls across 1 company, most recently for Arcutis Biotherapeutics, Inc. on February 27, 2024.
“On July 9, 2026, the Board appointed John Smither, the Company's current interim Chief Financial Officer, as Chief Financial Officer and principal financial officer of the Company, effective as of July 13, 2026.”
“Your initial position with the Company will be Chief Financial Officer, on an interim and part-time basis, 25 hours/week.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-01-01–present
-
Current
Start not stated–present
-
Start not stated–2025-04-29
Last confirmed by a filing; no departure on record
-
Start not stated–2021-03-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at GENELUX Corp
Other people whose current roles at this company are on record from its filings.
- Thomas D. Zindrick CEO, Board Member
- Lourie Zak CFO, Chief Accounting Officer
- Matt Pulisic CFO
- Matthew Pulisic CFO
- Eric Groen General Counsel
- James Tyree Board Member
- John Thomas Board Member
- Mary Mirabelli Board Member
- Thomas Zindrick Board Member
Leadership on record at MBX Biosciences, Inc.
Other people whose current roles at this company are on record from its filings.
- Steven Hoerter CEO, Chairman
- Ed Mathers Board Member
- Edward T. Mathers Board Member
- Laurie Stelzer Board Member
- Ora Pescovitz Board Member
- P. Kent Hawryluk Board Member
- Patrick J. Heron Board Member
- Steven Ryder Board Member
- Tiba Aynechi Board Member
- Tiba Aynechi, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $183,333 | $2,102,418 |
| 2023 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $200,886 | $1,036,225 |
| 2021 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $100,000 | $6,250,292 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.